AndroGel and Bupropion Interaction: Safety, Risks, and Clinical Guidance
HealthRX.com
No listed interaction, but each drug has separate risks
Key numbers
- 0.1%Seizure rate with sustained-release bupropion up to 300 mg a day (about 1 in 1,000 people)Source: accessdata.fda.gov, as cited Nov 7, 2026
- 0.4%Seizure rate with immediate-release bupropion at 300 to 450 mg a day (13 of 3,200 people)Source: accessdata.fda.gov, as cited Nov 7, 2026
- 7.0%Major adverse cardiovascular events in men on testosterone gel in TRAVERSE, versus 7.3% on placeboSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
From the public record
FDA adverse event reports listing both bupropion and testosterone
Through 2026-10-28, FDA had received 1,193 adverse event reports that list both bupropion and testosterone, out of 112,512 reports for bupropion and 41,579 for testosterone. A joint report shows both were recorded for the same person, not that they interacted.
| Measure | Value |
|---|---|
| Reports listing both drugs | 1,193 |
| All reports for bupropion | 112,512 |
| All reports for testosterone | 41,579 |
| Joint reports naming pain | 110 |
| Joint reports naming fatigue | 91 |
| Joint reports naming anxiety | 87 |
| Joint reports naming nausea | 66 |
How this was calculated
Counted FAERS reports that list both active substances in any role, then the symptom terms named most often in those reports. Terms about product use rather than symptoms were left out. The events may relate to either drug, to another drug, or to the illness.
Reports listing both bupropion and testosterone as single-ingredient active substances, any brand, suspect or concomitant
FAERS reports are unverified and do not prove the drug caused the event. Reporting rises with use, publicity and lawsuits, so these counts cannot give rates or risks and cannot be compared between drugs. Joint reports are not evidence of an interaction.
From the public record
Published papers mentioning both testosterone and bupropion
PubMed indexes 73 papers whose title or abstract mentions both testosterone and bupropion, 26 of them published from 2016 to 2025. For comparison, 103,536 papers mention testosterone and 5,784 mention bupropion.
| Measure | Value |
|---|---|
| Papers mentioning both | 73 |
| Of those, published 2016 to 2025 | 26 |
| Papers mentioning testosterone | 103,536 |
| Papers mentioning bupropion | 5,784 |
How this was calculated
Ran one PubMed title and abstract search requiring both names, and one search for each name alone. No filtering by study type or quality.
PubMed records naming both substances in the title or abstract, all article types and species
A paper that mentions both is not necessarily a study of their interaction, and may report no interaction. Counts include animal, cell and review papers.
At a glance
- Bupropion CYP2D6 warning covers / antidepressants, antipsychotics, beta-blockers, Type 1C antiarrhythmics [2]
- Generic testosterone gel 1.62% label interaction list / insulin and diabetes medicines, oral anticoagulants, corticosteroids or ACTH [4]
- Bupropion seizure risk / about 0.1% at up to 300 mg a day sustained-release; about 0.4% at 300 to 450 mg a day immediate-release [1]
- Seizure disorder / bupropion is contraindicated [2]
- Blood pressure / raised class-wide by testosterone products [3]; the naltrexone-bupropion label warns of blood pressure and heart rate increases [2]
- Heart outcomes / TRAVERSE used AndroGel 1.62%: major cardiovascular events 7.0% vs 7.3% on placebo [5][6]
Is there an interaction between the two?
Bupropion inhibits CYP2D6. The Contrave (naltrexone-bupropion) label says this can raise concentrations of antidepressants including SSRIs and many tricyclics, antipsychotics such as haloperidol, risperidone and thioridazine, beta-blockers such as metoprolol, and Type 1C antiarrhythmics such as propafenone and flecainide, and says a dose reduction of those drugs should be considered [2]. Given with a single 50 mg dose of metoprolol, Contrave raised metoprolol AUC about 4-fold and peak concentration about 2-fold [2].
The generic testosterone gel 1.62% label (Padagis) has a shorter interaction list: insulin and diabetes medicines, whose requirement may fall as androgens lower blood glucose; oral anticoagulants, where the label recommends more frequent INR and prothrombin time monitoring, especially when androgen therapy is started or stopped; and corticosteroids or ACTH, which together with testosterone may increase fluid retention [4]. Bupropion is not on that list, and testosterone is not among the CYP2D6 drugs the bupropion labeling names [2]. That label is for a generic gel rather than the AndroGel brand, and topical testosterone products can differ in strength, dose and systemic exposure [4].
Questions worth asking
Does bupropion change testosterone levels?
The bupropion labeling's interaction warnings concern drugs that bupropion affects through CYP2D6 and other pathways, and testosterone is not among the drugs it names [2].
Seizure risk sits on the bupropion side
The quantified, dose-related seizure risk belongs to bupropion. About 0.1% (1 in 1,000) of people taking sustained-release bupropion up to 300 mg a day have a seizure, and about 0.4% (13 of 3,200) of those taking immediate-release bupropion at 300 to 450 mg a day; for the immediate-release form the estimated incidence rises almost tenfold between 450 and 600 mg a day [1]. Gradual titration lowers the risk [1].
The Contrave label contraindicates bupropion in anyone with a seizure disorder or a history of seizures, in bulimia or anorexia nervosa, and during abrupt withdrawal from alcohol, benzodiazepines, barbiturates or antiepileptic drugs [2]. It also says to use extreme caution with other drugs that lower the seizure threshold, naming antipsychotics, antidepressants, theophylline and systemic corticosteroids, with low initial doses and gradual increases [2].
Blood pressure can rise with both
Testosterone products raise blood pressure. FDA's February 2025 labeling action followed required ambulatory blood pressure monitoring studies and stated that the completed studies confirmed a blood pressure increase with use of all testosterone products, class-wide; the agency required a new blood pressure warning for products that lacked one and product-specific data where monitoring studies had been done [3].
Bupropion can raise blood pressure too. The Contrave label, for the naltrexone-bupropion combination, says to monitor blood pressure and heart rate in all patients, especially those with cardiac or cerebrovascular disease, and contraindicates it in uncontrolled hypertension [2].
What TRAVERSE showed for the gel
FDA describes the TRAVERSE cardiovascular safety trial as having tested AndroGel 1.62% [5]. The trial randomized 5,246 men aged 45 to 80 with hypogonadism and existing or high risk of cardiovascular disease to daily 1.62% testosterone gel or placebo gel, with mean treatment of 21.7 months and mean follow-up of 33 months. Major adverse cardiovascular events occurred in 7.0% of men on testosterone gel versus 7.3% on placebo, hazard ratio 0.96 (95% CI 0.78 to 1.17) [6]. FDA reviewed the results and said they did not demonstrate a new safety signal or trend in adverse cardiovascular outcomes [5].
Check what you know
Question 1 of 3
Score: 0 right, 0 of 3 answered
Frequently asked questions
Can you take AndroGel with bupropion?
Does bupropion raise testosterone levels?
Can someone with a seizure disorder take bupropion?
Do AndroGel and bupropion both affect blood pressure?
Was AndroGel tested for cardiovascular risk?
References
Show all 7 referencesHide references
- U.S. Food and Drug Administration. Zyban (bupropion hydrochloride) prescribing information, 2017. Zyban prescribing information
- U.S. National Library of Medicine, DailyMed. Contrave Extended-Release (naltrexone and bupropion), Azurity (naltrexone hydrochloride and bupropion hydrochloride) prescribing information. Contrave Extended-Release (naltrexone and bupropion), Azurity (naltrexone hydrochloride and bupropion hydrochloride) label
- FDA issues class-wide labeling changes for testosterone products | FDA.
- U.S. National Library of Medicine, DailyMed. Testosterone gel 1.62% topical, generic (Padagis) prescribing information. Testosterone gel 1.62% topical, generic (Padagis) label
- Testosterone Information | FDA.
- Lincoff AM, Bhasin S, Flevaris P, Mitchell LM, Basaria S, Boden WE, et al. Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med. 2023;389(2):107-117.
- Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744.